<< Back to News

System Formulary Update
Hepatitis B Nucleos(t)ides

Situation

The Hepatitis B Nucleos(t)ides class review and formulary standardization was approved at the June 2021 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: adefovir, entecavir, tenofovir alafenamide

NOTE: lamivudine and  tenofovir disoproxil are also in this class, but were reviewed separately as part of the HIV NRTI Standardization

Assessment/Recommendations

Changes Effective: Tuesday, August 31, 2021

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Entecavir tablet: 0.5 mg
• Entecavir oral solution: 0.05 mg/mL

As a result, the following products will be removed from the inpatient drug formulary:

• Entecavir tablet: 1 mg
• Adefovir tablet: 10 mg